8-K
filed June 16, 2023, 7:59 PM ET
ticker TPST
CIK 0001544227
other material
confidence high
sentiment neutral
materiality 0.40
Tempest Therapeutics stockholders approve equity plan expansion and re-elect directors at 2023 annual meeting
Tempest Therapeutics, Inc.
- Stockholders approved Amended and Restated 2023 Equity Incentive Plan, increasing authorized shares by 1,150,000.
- Re-elected Thomas Dubensky and Christine Pellizzari as Class II directors to serve until 2026.
- Advisory vote on executive compensation approved with 7,355,907 votes for, 55,375 against.
- Ratified Ernst & Young as independent registered public accounting firm for fiscal 2023.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Tempest Therapeutics, Inc. shareholders approved Election of Class II directors at the 2023-06-15 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-15
Exact text from the filing
The Company’s stockholders elected the persons listed below as a Class II directors, to serve until the Company’s 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Tempest Therapeutics, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-15 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-15
Exact text from the filing
The Company’s stockholders ratified the selection of Ernst & Young LLP by the Audit Committee of the Board as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Tempest Therapeutics, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers at the 2023-06-15 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-15
Exact text from the filing
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Tempest Therapeutics, Inc. shareholders approved Approval of the Amended and Restated 2023 Equity Incentive Plan at the 2023-06-15 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-06-15
Exact text from the filing
The Company’s stockholders ratified the 2023 EIP, which amends, restates and will be a successor to, and replacement of, the 2019 EIP.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.